HC Wainwright & Co. Reiterates Buy on Coherus BioSciences, Maintains $13 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Douglas Tsao has reiterated a Buy rating on Coherus BioSciences (NASDAQ:CHRS), maintaining a $13 price target on the stock.
March 14, 2024 | 11:33 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. reaffirms a Buy rating on Coherus BioSciences with a $13 price target.
The reiteration of a Buy rating and maintenance of a $13 price target by a reputable analyst firm like HC Wainwright & Co. could instill confidence in investors about the future prospects of Coherus BioSciences, potentially leading to a positive short-term impact on the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100